Shionogi
CompanyJapanFounded 1919
Shionogi develops 3 assets, the furthest approved (edaravone in amyotrophic lateral sclerosis). Mostly small molecule acting on Oxidative stress and ROS signalling, lipid and ceramide metabolism and SLC5A2; based in Japan, founded in 1919.
- 3
- Assets
- Furthest stage
- Approved
- 7
- Trials
- 3
- Signals
Pipeline
3Free radical scavenger reducing oxidative stress in neurons.
Approved, Small molecule, Oxidative stress and ROS signalling, amyotrophic lateral sclerosis
HMG-CoA reductase inhibitor lowering LDL cholesterol.
Approved, Small molecule, Lipid and ceramide metabolism, SLC5A2, acute coronary syndrome (Phase 3), atherosclerosis (Phase 3)
Phase 2, Small molecule, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms6
- Trials23
- Signals6
- Similar companies6